Table 5 Expression of CD34, smooth muscle actin and glutamine synthetase in patients with chemotherapy-induced SOS
Case | Â | Histologic Grade | Trichrome | Immunohistochemistry Grade | Â | Â | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
No. | Agea | SI | NRH | VO | SOS-I | Â | CD34 | SMA | GS | CSI score | Chemotherapy (cycle #) |
1 | 70–74 | 3 | 1 | 0 | 4 | 1 | 3 | 3 | 0 | 6 | capecitabine and oxaliplatin (2) |
2 | 65–69 | 3 | 1 | 0 | 4 | 1 | 3 | 3 | 0 | 6 | FOLFOX (4) |
3 | 65–69 | 3 | 1 | 0 | 4 | 0 | 3 | 3 | 0 | 6 | capecitabin, oxaliplatin (2) and cetuximab |
4 | 55–59 | 3 | 1 | 0 | 4 | 0 | 3 | 1 | 3 | 7 | FOLFOX (*) and bevacizumab |
5 | 65–69 | 3 | 1 | 0 | 4 | 1 | 3 | 2 | 3 | 8 | FOLFOX (*) |
6 | 60–64 | 3 | 1 | 0 | 4 | 1 | 3 | 3 | 3 | 9 | FOLFOX (6) |
7 | 70–74 | 3 | 1 | 0 | 4 | 0 | 2 | 3 | 0 | 5 | FOLFOX and bevacizumab (6) |
8 | 50–54 | 2 | 1 | 0 | 3 | 1 | 0 | 0 | 0 | 0 | FOLFOX (6) |
9 | 70–74 | 2 | 1 | 0 | 3 | 1 | 2 | 0 | 0 | 2 | FOLFOX (*) |
10 | 65–69 | 2 | 1 | 0 | 3 | 0 | 2 | 3 | 0 | 5 | FOLFOX (*) and bevacizumab |
11 | 65–69 | 3 | 0 | 0 | 3 | 1 | 3 | 3 | 2 | 8 | FOLFOX (4) |
12 | 55–59 | 3 | 0 | 0 | 3 | 1 | 3 | 3 | 1 | 7 | FOLFOX (3) and bevacizumab |
13 | 75–79 | 2 | 1 | 0 | 3 | 0 | 3 | 0 | 0 | 3 | FOLFOX (*) |
14 | 70–74 | 0 | 1 | 2 | 3 | 1 | 0 | 3 | 3 | 6 | FOLFOX (12) |
15 | 30–34 | 1 | 1 | 0 | 2 | 0 | 2 | 3 | 0 | 5 | FOLFOX (8), converted to FOLFIRI and bevacizumab |
16 | 50–54 | 2 | 0 | 0 | 2 | 1 | 2 | 3 | 0 | 5 | FOLFOX (6) and cetuximab |
17 | 50–54 | 2 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | FOLFOX (8), converted to FOLFIRI, bevacizumab and cetuximab |
18 | 55–59 | 2 | 0 | 0 | 2 | 0 | 0 | 3 | 0 | 3 | FOLFOX (4) and bevacizumab |
19 | 45–49 | 2 | 0 | 0 | 2 | 1 | 1 | 3 | 3 | 7 | FOLFOX (5) and cetuximab converted to FOLFIRI |
20 | 55–59 | 1 | 1 | 0 | 2 | 0 | 1 | 0 | 0 | 1 | FOLFOX (6) |
21 | 55–59 | 2 | 0 | 0 | 2 | 1 | 2 | 3 | 0 | 5 | FOLFOX (*), converted to FOLFIRI, avastin and cetuximab |
22 | 50–54 | 1 | 1 | 0 | 2 | 1 | 2 | 0 | 0 | 2 | FOLFIRI and cetuximab |
23 | 55–59 | 1 | 0 | 0 | 1 | 1 | 0 | 2 | 0 | 2 | none |
24 | 60–64 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | none |
25 | 50–54 | 0 | 1 | 0 | 1 | 1 | 2 | 0 | 0 | 2 | none |
26 | 70–74 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | none |
27 | 60–64 | 1 | 0 | 0 | 1 | 1 | 0 | 3 | 0 | 3 | none |
28 | 55–59 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | none |
29 | 85–89 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | none |
30 | 75–79 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | none |